184439 YE ABS MASTERBATCH 186393 BK EVA MASTERBATCH WHITE SNOW OUTER TPE

WHITE ABS 199129 YE EVA MASTERBATCH 336942 YE PE MASTERBATCH

GEON E7370 WHITE 1205 0006119 OR STD PEBAX MASTERBATCH 10124429 OR PEBAX MASTERBATCH

183168 BU SAN MASTERBATCH 183173 BN SAN MASTERBATCH WHITE

Avient acquired the Clariant Masterbatch business (CMB) on July 1, 2020 (the “Acquisition Date”). Operating Income $3,783 $4,100 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Previous Guidance Current Guidance $3,783 $4,300 $308 $360 $308 $410 $1.93 $2.40 $1.93 $2.80 (1) (1)(1) (1)(1) (1) 12 BALANCE SHEET • Deleveraging to 1.9x net debt to adjusted EBITDA by the end of 2021 • Driven by record adjusted EBITDA performance and strong free cash flow generation from asset light business • Future cash deployment: M&A, opportunistic share repurchases and balance sheet / continued leverage reduction 3.5x 2.7x 1.9x Net Debt / Adjusted EBITDA ($ in millions) 2021E Adjusted EBITDA 560$ Free Cash Flow 275$ Total Debt 1,860 Less: Cash (800) Net Debt 1,060$ 2021E Net Debt / Adjusted EBITDA 1.9x (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition SUSTAINABILITY • Most recent Sustainability report substantially expanded disclosure on key environmental and social topics We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Masterbatch revenue synergies, that will drive 2021 revenue growth of 14% and long-term growth in excess of GDP o Clariant Masterbatch cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.

Executive Vice President and CFO, will provide insights and commentary on the company's growth expectations for the first quarter, strong financial position, as well as the status of the previously announced Clariant Masterbatch acquisition.  the time required to consummate the acquisition of Clariant's color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in Clariant's color and additive masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisition of Clariant's color and additive masterbatch business; our ability to achieve the strategic and other objectives relating to the proposed acquisition of Clariant's color and additive masterbatch business, including any expected synergies; our ability to successfully integrate Clariant's color and additive masterbatch business and achieve the expected results of the acquisition of Clariant's color and additive masterbatch business, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to raise or sustain prices for products or services; an ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisitions and integration, working capital reductions, costs reductions and employee productivity goals; information systems failures and cyberattacks; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.

STANDARD COLORS FOR BIOPHARMACEUTICAL APPLICATIONS GLASS FILL COLOR PRODUCT NAME Bright White HC8910-0004 RS 20% HC8910-0017 RS 33% HC8910-0018 RS Cool Gray 1C HC8910-0005 RS 20% HC8910-0006 RS Cool Gray 3C HC8910-0007 RS 20% HC8910-0008 RS Warm Gray 1 C HC8910-0009 RS 20% HC8910-0010 RS TPX 12-0703 Tan HC8910-0011 RS 20% HC8910-0012 RS 542C Blue HC8910-0013 RS 20% HC8910-0014 RS 301C Blue HC8910-0015 RS 20% HC8910-0016 RS Colors may vary from actual color shown

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below.

COLOR RAL REFERENCE COLOR RAL REFERENCE 1015 Brown/12 6026 Green/14 1034 Yellow/14 6032 Green/20 1018 Yellow/19 7004 Grey/21 1003 Yellow/20 8025 Brown/14 3020 Red/15 9022 Pearl Grey/1 5005 Blue/35 9010 White/5 5000 Blue/36